Why the study?
Does the SAGE-recommended IPV schedule maximize population immunity to type 2 poliovirus?
Does the SAGE-recommended IPV schedule maximize population immunity to type 2 poliovirus?
Current evidence from Demographic and Health Surveys is insufficient to determine if the SAGE-recommended IPV schedule maximizes population immunity to type 2 poliovirus.
Answers are grounded in this paper and cite their sources.
IPV at DTP3 may yield lowest coverage; leaves open whether SAGE schedule maximizes type 2 poliovirus immunity.
Coverage with 1 dose of IPV is expected to be lowest if it is administered at the DTP3 visit. At present, there is insufficient evidence to determine whether the SAGE-recommended IPV schedule for the polio endgame would maximize population immunity to type 2 poliovirus.
No takes yet. Share an insight, caveat, or question.
Anand et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: